Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer

Graham, LS; True, LD; Gulati, R; Schade, GR; Wright, J; Grivas, P; Yezefski, T; Nega, K; Alexander, K; Hou, WM; Yu, EY; Montgomery, B; Mostaghel, EA; Matsumoto, AA; Marck, B; Sharifi, N; Ellis, WJ; Reder, NP; Lin, DW; Nelson, PS; Schweizer, MT

Schweizer, MT (corresponding author), 1144 Eastlake Ave E,MS LG 454, Seattle, WA 98109 USA.

PROSTATE, 2021; 81 (7): 418

Abstract

Background Localized prostate cancers (PCs) may resist neoadjuvant androgen receptor (AR)-targeted therapies as a result of persistent intraprostatic ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索